Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.

被引：12

作者：

Hurwitz, Herbert

Hainsworth, John D.

Swanton, Charles

Perez, Edith A.

Sweeney, Christopher

Burris, Howard A.

Spigel, David

Meric-Bernstam, Funda

Strickland, Donald K.

Leon, Larry

Brammer, Melissa

Beattie, Mary Stanley

Bose, Ron

机构：

[1] Duke Univ, Med Ctr, Durham, NC USA

[2] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[3] UCL, Inst Canc, Sarah Cannon Res Inst, London, England

[4] Mayo Clin, Jacksonville, FL 32224 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] Washington Univ, Sch Med, St Louis, MO USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

653

引用

页数：1